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ABSTRACT 
Intraperitoneal injection of adult male mice with the neuroactive steroid dehydroepiandrosterone 
sulfate (DHEAS) at 1 and 40 mg/kg caused dose-dependent increases in the concentration of 
both this compound and its corresponding free steroid DHEA in brain within 1 h of injection. 
Pretreatment of these animals for 24 h with the steroid sulfatase inhibitor COUMATE at a dose 
(10 mg/kg, p.o.) shown previously to cause almost complete inhibition of this enzyme in liver 
and brain was expected to increase the amount of the DHEAS dose reaching the brain. 
Surprisingly however, the increases in brain concentrations of DHEAS and DHEA after injection 
of DHEAS i.p. were attenuated by pretreatment with COUMATE. The results suggest that the 
arylsulfamate based steroid sulfatase inhibitors such as COUMATE interfere with the influx of 
the DHEAS anion into the brain.  
 
Section: Regulatory Systems 
 





DHEAS, dehydroepiandrosterone sulfate 
GABA, γ-aminobutyric acid 
NMDA, N-methyl-D-aspartate 
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1. Introduction 
 
Since the characterization of dehydroepiandrosterone sulfate (DHEAS) as a brain steroid 
(Corpéchot et al. 1981) there has been detailed investigation of the effects of this compound on 
neural function (see Gibbs et al. 2006). Of particular interest in view of the decline in plasma 
DHEAS of adrenal origin with human ageing is the ability of this steroid to improve retention of 
memory after subcutaneous or intracerebral injection in mice (Flood et al. 1988).  Several studies 
have since shown DHEAS administered either systemically or directly into the brain to enhance 
the acquisition and consolidation of memory and reverse pharmacologically induced amnesia in 
a variety of species (see Wolf and Kirschbaum 1999). Possible neural sites of action for the 
above effects of DHEAS include antagonism of GABAA receptors (Majewska et al., 1990) and 
stimulation of sigma receptors, the latter underlying an enhancement of NMDA receptor function 
(Monnet et al., 1995; see also Maurice et al., 2006). Additional modes of action are likely for 
DHEAS and its corresponding free steroid dehydroepiandrosterone (DHEA), in particular to 
explain the antiglucocorticoid and neuroprotective effects of these compounds (see Wolf and 
Kirschbaum 1999).   
 
In addition to enhancement of memory, other behavioral effects of DHEAS in mice include 
anxiolysis on the elevated plus maze (Melchior and Ritzmann 1994) and increased attack 
behavior against a conspecific male (Nicolas et al., 2001). The latter is correlated with the 
expression of liver steroid sulfatase (STS; Le Roy et al., 1999), an enzyme which is also present 
in brain (Mortaud et al., 1996) and which catalyses the hydrolysis of 3β-hydroxysteroid sulfates 
such as DHEAS to liberate the free steroid DHEA. Several irreversible inhibitors of this enzyme 
have become available in recent years, all of which feature an arylsulfamate moiety (see 
Nussbaumer and Billich 2004). Although developed primarily as potential therapeutic agents for 
the treatment of estrogen- and androgen-dependent disorders of peripheral tissues, these STS 
inhibitors would be expected to increase the potency of steroid sulfates, at least for their direct 
actions at the receptor sites in the brain described above. Indeed, a previous study by one of us 
(Nicolas et al., 2001) showed that prior treatment of mice with the STS inhibitor COUMATE (7-
O-sulfamoyl)-4-methylcoumarin) decreased the dose of intraperitoneally administered DHEAS 
needed to elicit aggressive behavior. At the time, this observation was interpreted as evidence for 
inhibition of STS allowing more of the circulating DHEAS to cross the blood-brain barrier. We 
now report that the opposite is the case and that pretreatment with the STS inhibitor COUMATE 




As can be seen from Fig. 1, treatment with COUMATE had no significant effect on the 
concentrations of endogenous DHEAS or DHEA in the mouse brain after 24 h. The 
intraperitoneal administration of DHEAS to these mice caused a dose-dependent increase in the 
concentration of both this compound and its desulfated free steroid DHEA in the brain within 1 h 
of injection. However, such increases in the brain concentrations of DHEAS and DHEA were 
lower in animals which had been pre-treated with the STS inhibitor COUMATE. The ratios of 
DHEAS to DHEA were higher (P<0.05) in mice injected with the 40 mg/kg compared to the 1 
mg/kg dose of DHEAS, but these ratios were not altered significantly by COUMATE 
pretreatment (with methyl cellulose pretreatment DHEAS: DHEA 1.95 0.60 after 1 mg/kg and 
9.55 1.50 after 40 mg/kg DHEAS; with COUMATE pretreatment DHEAS: DHEA 1.03 0.12 
after 1 mg/kg and 21.23 8.62 after 40 mg/kg DHEAS).  
 3. Discussion 
 
The endogenous concentrations of both DHEA and DHEAS were close to previously reported 
values for mouse (Young et al., 1996; Le Goascogne et al., 2000; Tagawa et al., 2006) and rat 
(Corpéchot et al. 1981; Mathur et al., 1993; Ebner et al., 2006) brain. No other steroids have been 
reported in these tissues at concentrations likely to cross-react with the antibodies used in the 
present assays. The same may not be true after dosing with exogenous DHEAS. However, the 
major metabolites in rat and monkey brain after systemic administration of DHEAS appear to be 
DHEA and androstenediol (Knapstein et al., 1968; Kishimoto and Hoshi 1972) which, in view of 
the complete separation of free steroids and steroid sulfates prior to assay in the present study, 
would not cause interference with the DHEAS measurements reported here. Indeed, the 
surprising observation of the present study is that inhibition of STS with COUMATE results in 
reduced concentrations of DHEAS in the brain after the systemic administration of this steroid.  
  
To the best of our knowledge, the only other study to investigate concentrations of DHEAS in 
brain after treatment with STS inhibitors has employed chronic dosing of rats (Johnson et al., 
1997). Here, daily doses of the STS  inhibitor (p-O-sulfamoyl)-N-tetradecanoyl tyramine (DU-
14) over 15 days caused a 77.6% increase in whole brain DHEAS. In the present experiments, 
there was no significant change in endogenous DHEAS or DHEA 24 h after a single dose of 
COUMATE. However, a low level of 3β-hydroxysteroid sulfotransferase activity has been 
reported in brain tissue (Rajkowski et al., 1997) and accumulation of DHEAS formed from 
endogenous DHEA might be expected after chronic inhibition of STS. The dose of COUMATE 
used in the present experiments had been shown previously to inhibit STS activity in liver and 
brain by 87% and 71%, respectively, by the time at which mice were treated with DHEAS 
(Nicolas et al. 2001). The increased sensitivity of these COUMATE-treated mice to the 
aggression enhancing effects of DHEAS now looks unlikely to be due simply to higher amounts 
of this sulfated steroid entering and/or accumulating in the brain, unless there are localized 
changes which have been missed in the present experiments. Interestingly, bell-shaped dose–
response curves for intraperitoneally administered DHEAS have been observed both for the 
above aggression enhancing effects in mice (Nicolas et al. 2001) and for memory enhancing 
effects in rats (Li et al., 1997), with and without STS inhibition. Thus the rate as well as the 
absolute amount of DHEAS entering the brain could be a factor determining the effects of this 
steroid on behavior. Alternatively, the possibility cannot be excluded that DHEAS is enhancing 
aggression in mice by acting outside of the brain. Two likely such sites of action are the olfactory 
and vomeronasal sensory epithelia, which lie outside of the blood-brain barrier and which are 
known to be essential for attack behavior between male mice (Stowers et al., 2002; Mandiyan et 
al., 2005).    
 
As expected, the present results show reduced formation of DHEA from DHEAS after STS 
inhibition with COUMATE Little is known of the impact of COUMATE on other steroids 
although a recent clinical trial of the tricyclic coumarin sulfamate 667 COUMATE in women 
with breast cancer reported no change in endogenous circulating DHEAS or estrone sulfate but 
significant reductions in serum concentrations of DHEA, androstenedione, androstenediol, 
testosterone, estradiol and estrone (Stanway et al., 2006). As mentioned above, the major 
metabolites found in rat and monkey brain after systemic administration of DHEAS appear to be 
DHEA and androstenediol. Although both androgens, the latter has estrogenic properties 
(Poortman et al., 1975) and COUMATE itself is devoid of such activity (Purohit et al., 1996). 
From the above evidence, we can suggest that pretreatment of mice with COUMATE is likely to 
have led to reduced stimulation of both androgen and estrogen receptors in the brain following 
dosing with DHEAS. The present results also indicate the COUMATE pretreatment would have 
led to reduced antagonism of GABAA receptors and stimulation of sigma receptors in the brain 
(see Introduction) after systemic injection of DHEAS. Again, we are led to speculation that a 
possible site of action for DHEAS in enhancing aggression of these COUMATE-treated mice 
lies outside of the blood-brain barrier. 
 
How might the STS inhibitor COUMATE reduce entry of systemic DHEAS into the brain? As a 
charged conjugate, DHEAS is thought to be less permeable through the blood-brain barrier than 
its corresponding free steroid DHEA and experiments in monkeys (Knapstein et al., 1968) and 
rats (Kishimoto and Hoshi 1972) have shown only a small proportion of circulating DHEAS to 
enter the brain. This entry is likely to be through an anion transporter. Such transporters have 
been found in the blood-brain barrier, although investigated for their role in the efflux rather than 
the influx of DHEAS (Asaba et al., 2000; Lee et al., 2005). The possibility arises that anion 
transporters can also facilitate the influx of DHEAS into the brain and are inhibited by 
COUMATE and other aryl-sulfamate based STS inhibitors. This would limit access of DHEAS 
to the brain, especially under conditions of raised circulating concentrations. Interestingly, in 
view of our speculation above that DHEAS might be enhancing aggression in mice through 
acting peripherally to influence olfaction, organic anion transporters have recently been 
identified in both the main olfactory and vomeronasal epithelial layers and shown to transport a 
steroid sulfate (Kaler et al., 2006). Moreover, one of the adverse events reported from the clinical 
trial of 667 COUMATE (Stanway et al., 2006) was taste disturbance.     
 
To conclude, the present observations indicate that STS inhibitors such as COUMATE cannot 
always be assumed to increase the concentrations of DHEAS in the brain. This caution is likely 
to be even more apposite in those animals such as primates with higher levels of circulating 
DHEAS of adrenal origin and has implications for the neurological health of patients treated with 
STS inhibitors for steroid-dependent tumours and other disorders. 
 
4. Experimental Procedures 
 
Treatments of male mice with COUMATE and DHEAS were chosen according to the previous 
study of aggressive behavior (Nicolas et al, 2001) and using the same CBA/H colony. Animals 
were kept in a 12:12 photoperiod (lights on at 8am) at 23.5  0.5°C with food and water 
available ad libitum. Each male was individually housed with a female, generally a littermate and 
experiments took place at 12-16 weeks of age. Animal care followed C.N.R.S. protocols and 
guidelines. The STS inhibitor COUMATE (10 mg/kg) or its vehicle of 0.5% w/v methylcellulose 
in 0.9% NaCl was administered p.o. (5 ml/kg) 24 h before mice were killed for brain samples. 
Then, 1 h before they were killed, the animals were injected with DHEAS (1 or 40 mg/kg, i.p., 
10 ml/kg) or the water vehicle alone. Mice were killed by cervical dislocation and decapitation. 
Their brains (including olfactory bulbs and cerebellum) were rapidly removed and frozen in 
liquid nitrogen before storage at –80°C. The COUMATE was synthesized by Gérald Guillaumet 
(I.C.O.A, Orléans, France) according to Purohit et al. (1996) and DHEAS purchased as the 
sodium salt from Sigma® Chemical Co (St Louis, MO, USA).  
 
Brain steroid extraction and fractionation was essentially as described by Ebner et al. (2006). 
Each brain was homogenized in 5 volumes (w/v) of ice-cold potassium phosphate buffer (5 mM, 
pH 7) with a Polytron® blender then added dropwise to 20 volumes of acetic acid (3%, v/v) in 
96% ethanol in an ultra-sonicating bath. The extract was deproteinised by centrifugation 
(28000 g, 30 min) and delipidated by partitioning three times against 10 volumes of isooctane 
followed by passage (in 60% ethanol) through a 60 mg reverse phase Oasis hydrophilic-
lipophilic balance HLB  cartridge. Extracts were then dried down under vacuum, redissolved in 
20% ethanol and loaded onto 60 mg reverse phase Oasis mixed-mode anion exchange MAX  
cartridges for separation of free and sulfated steroids. After a wash with 5 ml of 20% ethanol in 
ammonium acetate (20 mM, pH 7), the free steroids were eluted with 4 ml ethyl acetate. Passage 
of 20% ethanol in formate/pyridine (20 mM, pH 3) removed any steroid glucuronides present 
and the steroid sulfates could then be eluted with 15 ml of 1% w/v ammonium carbonate in 60% 
ethanol. Silanised glassware was used throughout and all solvents redistilled from AR grade 
(VWR International, Leicestershire, UK). The Oasis HLB  and MAX  cartridges were 
purchased from Waters Corp., Milford, USA. One brain from each of the six different treatments 
was included in every batch of samples extracted and fractioned for steroid radioimmunoassay 
and each batch also included normal mouse brain homogenates to which 2 pmol of either 
DHEAS or DHEA had been added to check their recoveries through the above procedure. 
 
Free and sulfated steroid fractions were dried down under nitrogen at 60°C and redissolved in 
phosphate buffered saline containing 3% w/v bovine serum albumin and 0.01% thimerosal w/v 
for radioimmunoassay. All assay components were dissolved in the same buffer to a total volume 
of 0.25 ml. The measurement of DHEA in the free steroid fraction employed 
3
H-DHEA at 0.25 
nM and anti-DHEA antibodies at a dilution of 1:12500. In order to assay DHEAS in the steroid 
sulfate fraction, we employed 
3
H-DHEAS at 0.25 nM and anti-DHEAS antibodies at 1:14300. 
After incubation for at least 2 h at room temperature, both sets of immunoassays were terminated 
by the addition of 25 µl of a heat-killed, formalin-fixed 1% v/v suspension of Staphylococcus 
aureus cells (Pansorbin®, Calbiochem, USA), followed by 3 ml of ice-cold PBS and rapid 
filtration through glass-fibre filters (GF/C, Whatman, UK) under vacuum. Filters were then 
placed in 3 ml of scintillation fluid (Ecoscint H, National Diagnostics, UK) for the measurement 
of antibody bound 
3
H-label. All measurements were made in triplicate and a range of unlabelled 
standard concentrations included in each assay for the construction of calibration curves. Both 
antibodies were purchased from ICN Biomedicals Inc. USA and supplied with the following % 
cross reactions for anti-DHEA and anti-DHEAS, respectively: DHEA 100.00 and 58.50, DHEAS 
1.18 and 100.00, androstenedione 0.32 and 39.70, androsterone 0.02 and 30.52, pregnenolone 
0.02 and <0.01, estrone <0.01 and 0.67, testosterone <0.01 and 0.61. In addition, the following 
compounds were given as <0.01% cross-reaction with either antibody: aldosterone, cholesterol, 
corticosterone, cortisol, desoxycorticosterone, 17β-estradiol, estriol, 17α-hydroxypregnenolone, 
17α-hydroxyprogesterone, 5α-dihydrotestosterone. The label employed was [1,2,6,7-3H(N)]- 
DHEA (PerkinElmer, UK; 3422.5 GBq/mmol). For use in the assays of DHEAS, this label was 
sulfated with triethylamine sulfur trioxide (Dusza et al. 1968), cleaned by solvent extraction 
(Corsan et al. 1997) and then purified by celite chromatography in the solvent system (v/v) 
isooctane (20); tert-butanol (40): water (39): ammonia (1). Thin layer chromatography of the 
final product on silica gel 60 coated plates in ethyl acetate/ethanol/ammonia (25/10/2 v/v) 
revealed a purity of greater than 99%. Student’s t-test was used to evaluate the significance of 
differences in brain DHEAS and DHEA concentrations between mice pretreated with 
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Fig. 1 Effects of steroid sulfatase inhibition with COUMATE (10 mg/kg, p.o., 24 h) on the 
concentrations of (A) DHEAS and (B) DHEA in adult male mouse brain following 
intraperitoneal injection of DHEAS (1 or 40 mg/kg, 1 h). Animals not pre-treated with 
COUMATE were instead given a control injection of the vehicle alone (0.5% w/v 
methylcellulose in 0.9% NaCl) and the vehicle for DHEAS was distilled water. All values shown 
as mean  SEM (n = 5 mice) and uncorrected for recoveries in the extraction and fractionation of 
steroids from brain homogenates, which were as follows: DHEAS 30.2  4.6% ; DHEA 107.1  
7.1% (both values mean  SEM; n = 10). *P<0.05 for significance of difference between mice 
pre-treated with COUMATE or the methylcellulose vehicle alone then injected with the same 
dose of DHEAS.  
 
 
